Yahoo Finance | EN590 Commodities
EN590 Commodities GroupMarket Analysis 2026-09-18T16:51:22+00:00
Gilead Sciences, Inc. (NASDAQ:GILD) has reached an agreement with the Pan American Health Organization (PAHO) to expand access to its twice-yearly HIV-prevention drug lenacapavir across Latin America and the Caribbean. The agreement creates a regional procurement pathway through PAHO for 14 countries, including Brazil, Mexico, Argentina, Colombia and Peru, that were outside Gilead's existing voluntary generic-licensing arrangements. Availability will still depend on individual countries' regulatory approvals and decisions to adopt the drug. Reuters notes that new HIV infections in Latin America and the Caribbean increased 13% between 2010 and 2024, highlighting a sizeable unmet prevention need. Gilead expects lenacapavir to generate about $1 billion in 2026 sales. The agreement could broad
About EN590 Commodities Group
25+ years in mineral exploration and extraction. 15+ years of global commodity trading. Based in New York, USA serving 75+ countries.